Mitochondrial dysfunction, α-synuclein and Parkinson's disease

doi:10.3969/j.issn.1006-7795.2015.06.006

Abstract

Abstract: Parkinson's disease(PD) is a common neurodegenerative disorder. The disease is characterized by the loss of dopamine neurons in the substantia nigra and the presence of intraneuronal Lewy bodies. Many studies suggest that mitochondrial dysfunction is the central pathogenesis of PD. The abnormal aggregation of α-synuclein is the key factor in the cascade of PD pathological events. Recently, the interaction between α-synuclein and mitochondrial dysfunction has attracted much attention, but the exact mechanism underlying PD pathogenesis is still unclear. In this review, we discuss the key roles of mitochondria and α-synuclein in the pathogenesis of PD and the interaction between them. Understanding the functional consequences of α-synuclein's interactions with mitochondria is likely to provide important insights into disease pathophysiology, and may also reveal therapeutic strategies.

Key words: Parkinson's disease, α-Synuclein, mitochondria

CLC Number:

R741

Zhang Ruyi, Zhang Li, Li Lin. Mitochondrial dysfunction, α-synuclein and Parkinson's disease[J]. Journal of Capital Medical University, 2015, 36(6): 861-864.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2015.06.006

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2015/V36/I6/861

References

[1] Bekris L M, Mata I F, Zabetian C P. The genetics of Parkinson disease[J]. J Geriatr Psychiatry Neurol, 2010,23(4):228-242.
[2] Peng X, Tehranian R, Dietrich P, et al.Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells[J]. J Cell Sci, 2005,118(Pt15):3523-3530.
[3] Zhao D L, Zou L B, Zhou L F, et al. A cell-based model of alpha-synucleinopathy for screening compounds with therapeutic potential of Parkinson's disease[J]. Acta Pharmacol Sin, 2007,28(5):616-626.
[4] Perez R G, Waymire J C, Lin E, et al. A role for alpha-synuclein in the regulation of dopamine biosynthesis[J]. J Neurosci, 2002,22(8):3090-3099.
[5] Koch J C, Bitow F, Haack J, et al. Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons[J]. Cell Death Dis, 2015,6:e1811.
[6] Prots I, Veber V, Brey S, et al. α-Synuclein oligomers impair neuronal microtubule-kinesin interplay[J]. J Biol Chem, 2013,288(30):21742-21754.
[7] Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease[J]. Nat Genet, 2009,41(12):1303-1307.
[8] Lee V M, Trojanowski J Q. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery[J]. Neuron, 2006,52(1):33-38.
[9] Volpicelli-Daley L A, Luk K C, Patel T P, et al. Exogenous α-synuclein fibrils induce Lewy bod pathology leading to synaptic dysfunction and neuron death[J]. Neuron, 2011,72(1):57-71.
[10] Gómez-Santos C, Ferrer I, Reiriz J, et al. MPP+ increases α-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells[J]. Brain Res, 2002,935(1-2):32-39.
[11] Banerjee R, Starkov A A, Beal M F, et al. Mitochondrial dysfunction in the limlight of Parkinson's disease pathogenesis[J]. Biochim Biophys Acta, 2009,1792(7):651-663.
[12] Braak H, Ghebremedhin E, Rüb U, et al. Stages in the development of Parkinson's disease-related pathology[J]. Cell Tissue Res, 2004,318(1):121-134.
[13] De Vos K J, Grierson A J, Ackerley S, et al. Role of axonal transport in neurodegenerative diseases[J]. Annu Rev Neurosci, 2008,31:151-173.
[14] Roy S. The paradoxical cell biology of α-synuclein[J]. Results Probl Cell Differ, 2009,48:159-172.
[15] Schapira A H. Cooper J M, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease[J]. J Neurochem, 1990,54(3):823-827.
[16] Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance[J]. Ann N Y Acad Sci, 2008,1147:93-104.
[17] Ferrer I. Neuropathology and neurochemistry of non motor symptoms in Parkinson's disease[J]. Parkinsons Dis, 2011:708404.
[18] Zaminelli T, Gradowski R W, Bassani T B, et al. Antidepressant and antioxidative effect of ibuprofen in the rotenone model of Parkinson's disease[J]. Neurotox Res, 2014,26(4):351-362.
[19] Jiang H, Wu Y C, Nakamura M, et al. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H₂O₂- and Sin-1-induced cell death[J]. Neurobiol Aging, 2007,28(11):1709-1717.
[20] Parihar M S, Parihar A, Fujita M, et al. Mitochondrial association of alpha-synuclein causes oxidative stress[J]. Cell Mol Life Sci, 2008,65(7-8):1272-1284.
[21] Wu F, Poon W S, Lu G, et al. α-Synuclein knockdown attenuates MPP+ induced mitochondrial dysfunction of SH-SY5Y cells[J]. Brain Res, 2009,1292:173-179.
[22] Martin L J, Pan Y, Price A C, et al. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death[J]. J Neurosci, 2006,26(1):41-50.
[23] Betts-Henderson J, Jaros E, Krishnan K J, et al. Alpha-synuclein pathology and Parkinsonism associated with POLG1 mutations and multiple mitochondrial DNA deletions[J]. Neuropathol Appl Neurobiol, 2009,35(1):120-124.
[24] Chinta S J, Mallajosyula J K, Rane A, et al. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo[J]. Neurosci Lett, 2010,486(3):235-239.
[25] Devi L, Raghavendran V, Prabhu B M, et al. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain[J]. J Biol Chem, 2008,283(14):9089-9100.
[26] Nakamura K, Nemani V M, Wallender E K, et al. Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria[J]. J Neurosci, 2008,28(47):12305-12317.
[27] Nakamura K, Nemani V M, Azarbal F, et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein[J]. J Biol Chem, 2011,286(23):20710-20726.
[28] Xie W, Chung K K. Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson's disease[J]. J Neurochem, 2012,122(2):404-414.
[29] Dawson T M, Ko H S, Dawson V L. Genetic animal models of Parkinson's disease[J]. Neuron, 2010,66(5):646-661.
[30] Zhang N Y, Tang Z, Liu C W. alpha-Synuclein protofibrils inhibit 26S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis[J]. J Biol Chem, 2008,283(29):20288-20298.